Background Gemtuzumab ozogamicin (GO) is effective as single agent in the treatment of
acute myeloid leukemia (AML). We evaluated efficacy and safety of a chemotherapy …

Background The benefit of gemtuzumab ozogamicin (GO) in combination with
chemotherapy as frontline therapy in patients with acute myeloid leukemia (AML) is still …

BACKGROUND: Elderly patients with acute myeloid leukemia (AML) are generally unable to
withstand the rigors of intensive induction chemotherapy and its attendant complications …

Background: In this study, the effectiveness and safety of combining gemtuzumab
ozogamicin (GO) with an abbreviated schedule of standard induction chemotherapy were …

Purpose This randomized trial evaluated the efficacy and toxicity of sequential gemtuzumab
ozogamicin (GO) and standard chemotherapy in older patients with newly diagnosed acute …

BACKGROUND AND OBJECTIVES: Acute myeloid leukemia (AML) in the elderly is
associated with low rates of response to conventional chemotherapy and long-term survival …

Gemtuzumab ozogamicin (GO), an anti-CD33 monoclonal antibody conjugated to
calicheamicin, is effective as single agent in the treatment of poor risk acute myeloid …

The value of the combination of gemtuzumab ozogamicin (GO) and chemotherapy for the
treatment of acute myeloid leukemia (AML) is currently analyzed within clinical trials. GO (6 …

The prognosis of acute myeloid leukemia (AML) in older adults is generally poor. Standard
cytotoxic chemotherapy is usually poorly tolerated and provides dismal results in this patient …

Purpose There has been little survival improvement in older patients with acute myeloid
leukemia (AML) in the last two decades. Improving induction treatment may improve the rate …